Project

GO41717: A Phase III, randomized, double-blinded, place-bo-controlled study of Tiragolumab, an Anti-Tigit Antibody, in combination with Atezolizumab compared with placebo in combination with Atezolizumab in patients with previously untreated locally advanced unresectable or metastatic PD-L1 selected Non-Small Cell Lung Cancer

Scheduled · 2020 until 2024